OTCMCFRXQ
Market cap0kUSD
Dec 20, Last price
0.00USD
1Q
0.00%
IPO
-100.00%
Name
ContraFect Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-1.28%
Rev. gr., 5y
%
Revenues
0k
Net income
-66m
L
CFO
-46m
L+11.79%
Profile
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 56,889 | 47,265 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (56,889) | (47,265) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 545 | (27,131) | |||||||
Tax Rate | |||||||||
NOPAT | (57,434) | (20,134) | |||||||
Net income | (65,698) -1,059.23% | 6,849 -124.47% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 57,500 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 671 | 657 | |||||||
Long-term debt | 4,420 | 5,218 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 9,481 | 2,603 | |||||||
Net debt | (8,591) | (48,410) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (45,974) | (41,125) | |||||||
CAPEX | (62) | ||||||||
Cash from investing activities | 32,083 | (11,613) | |||||||
Cash from financing activities | 6 | 53,907 | |||||||
FCF | (53,172) | (19,698) | |||||||
| Balance | |||||||||
Cash | 13,682 | 54,285 | |||||||
Long term investments | |||||||||
Excess cash | 13,682 | 54,285 | |||||||
Stockholders' equity | (325,736) | (260,632) | |||||||
Invested Capital | 326,246 | 315,877 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 521 | 460 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (56,735) | (47,117) | |||||||
EV/EBITDA | |||||||||
Interest | 545 | ||||||||
Interest/NOPBT | |||||||||